CIK 0001287098
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
MAXCYTE, INC.
Sign in to watch- Ticker
- MXCT
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 522210438
- Phone
- +1 301-517-5556
- Business address
- 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
- Former names
- MAXCYTE INC
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Grant or award Director acquired 29,210 shares (grant or award)
- 4 Open-market sale Chief Commercial Officer sold 1,211 shares at $3.18 ($3,850)
- 4 Open-market sale GENERAL COUNSEL sold 353 shares at $3.18 ($1,122)
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 6,939 shares at $3.18 ($22,061)
- 4 Grant or award Chief Commercial Officer acquired 34,625 shares (grant or award)
- 4 Grant or award GENERAL COUNSEL acquired 23,125 shares (grant or award)
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 37,500 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 3,000 shares at $4.65 ($13,935)
- 4 Open-market sale GENERAL COUNSEL sold 4,466 shares at $4.54 ($20,272)
- 4 Planned sale Director sold 3,000 shares at $4.01 ($12,021)
- 4 Planned sale Director sold 3,000 shares at an average $3.78 ($11,328)
- 4 Planned sale Director sold 47,689 shares at $3.72 ($177,403)
- 4 Planned sale Director sold 3,000 shares at $3.72 ($11,166)
Page 2 of 9 · 163 filings